AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 53 min read$HCAT

Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For

Health Catalyst (NASDAQ: HCAT) is set to report Q2 earnings Thursday after the bell. Last quarter, it reported revenue of $70.76M, down 10.9% YoY, and missed next-quarter guidance versus analysts. Consensus expects Q2 revenue to fall 14.6% YoY. HCAT stock is near $2.28 with an average analyst price target of $2.31.

Original reporting
financialcontent.com
Published Aug 5, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For — source image
Source · financialcontent.com
Decision brief

The 30-second read

$HCATNeutralMed
01

Why it matters

Traders should focus on whether reported revenue and any forward guidance reverse the expected YoY decline, since the text highlights both the consensus expectation and the prior quarter’s guidance miss.

02

Market read

This is a pre-earnings setup for HCAT with specific consensus revenue expectations and a reminder of last quarter’s guidance miss, implying meaningful event risk.

03

What to watch

The article does not quantify margins, bookings, or customer concentration, which can dominate post-earnings moves even when revenue growth slows.

Relevance 4/10Novelty 4/10Timing: pre-market into Thursday after-the-bell earnings

Background

The article frames HCAT’s upcoming Q2 earnings as a test of whether recent softness and a prior guidance miss persist.

Company-level read

Ticker impact

$HCATNeutralMedium confidence
Context

Health Catalyst (HCAT) is set to report earnings Thursday after the bell, with consensus expecting a 14.6% YoY revenue decline.

Expected impact

Likely elevated volatility into the print; direction depends on revenue/guidance versus the stated consensus and prior quarter’s guidance miss.

Evidence & confidence

The article provides specific upcoming timing (after the bell Thursday) and concrete consensus expectations (14.6% YoY decline) plus a reminder that last quarter’s guidance missed, which are key inputs for pre-earnings risk/reward.

Market effects

Sector

Read-through to data and analytics software demand expectations, since the piece references peer results and recent sector strength.

Regional

No specific regional impact described beyond US-listed sentiment.

Global

No explicit global linkage beyond general sector performance.

Counterpoint

What could challenge this read

Despite the expected revenue decline, HCAT’s history of exceeding expectations could mean the market is underestimating upside if guidance stabilizes.

Key entities

  • company
    Health Catalyst

    NASDAQ-listed healthcare data analytics firm reporting earnings Thursday after the bell.

  • company
    Palantir Technologies

    Peer cited as having delivered strong YoY revenue growth and a post-results stock jump.

  • company
    Strategy

    Peer cited as having reported revenues up 6.9% and a post-results stock decline.

Read at source← All news

Related articles

AUG 13
$HCATMedAI 8/10

Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.

fool.com6 min
AUG 7
$HCATHighAI 9/10

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.

financialcontent.com4 min
AUG 6
$HCATMedAI 8/10

M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix

Health Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.

hitconsultant.net4 min
AUG 6
$HCATHigh

Health Catalyst, Inc. (HCAT): Results of Operations and Financial Condition

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Second Quarter 2026 Results SALT LAKE CITY, UT, August 6, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financ

SEC EDGAR 8-K6 min
AUG 28
$NVDAMedAI 8/10

NVIDIA (NVDA), Palantir Technologies (PLTR), and the AI Achilles’ Heel: Steve Eisman’s Concentration Warning Explained

Steve Eisman warned on CNBC that OpenAI and Anthropic contribute significantly to the revenue of major tech companies, posing a concentration risk. NVIDIA (NVDA) and Palantir (PLTR) are exposed to this risk differently. NVIDIA reported strong cash flow, while Palantir saw revenue growth and raised guidance. Michael Burry highlighted NVIDIA's reliance on a few hyperscale customers and potential financing risks. Both companies face unique challenges and opportunities related to AI.

insidermonkey.com3 min